Amphotericin B

Concomitant administration is contraindicated due to nephrotoxic potential. Must be discontinued at least 7 days prior to cidofovir therapy.

Concomitant administration of cidofovir and amphotericin B is contraindicated due to nephrotoxic potential. Must be discontinued at least 7 days prior to cidofovir therapy.

May enhance potential for renal toxicity, bronchospasm, and hypotension. Should be given concomitantly only with great caution.

Concomitant use with corticosteroids may cause hypokalemia, cardiac enlargement, and congestive heart failure.

May potentiate amphotericin B-induced hypokalemia, predisposing to cardiac dysfunction. Avoid concomitant use unless necessary; monitor serum electrolytes and cardiac function.

Increased nephrotoxicity may result from combined effect with cyclophosphamide.

Nephrotoxic agent that may enhance potential for drug-induced renal toxicity. Use concomitantly only with great caution and intensive monitoring of renal function.

Concomitant use with corticosteroids may cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure.

Concomitant use may lead to hypokalemia and has been associated with cardiac enlargement and congestive heart failure.

Concomitant use may cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure.

Concomitant use with amphotericin B may cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure.

Amphotericin B-induced hypokalemia may potentiate digitalis toxicity. Monitor serum potassium levels and cardiac function.

Concurrent use may increase toxicity of flucytosine by increasing cellular uptake and/or impairing renal excretion.

Enhanced hypokalemia. Requires frequent serum potassium monitoring and potassium supplementation.

Concomitant use should be avoided due to additive nephrotoxicity and renal impairment risk.

Increased risk of nephrotoxicity and potential increase in serum creatinine. Monitor renal function.

Coadministration may increase risk of nephrotoxicity and serum creatinine elevation. Monitor renal function closely.

Concomitant use may cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure.

Concomitant use with amphotericin B and hydrocortisone has been followed by cardiac enlargement and congestive heart failure. Close monitoring for hypokalemia required.

Concomitant use with corticosteroids can cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure.

Acute pulmonary toxicity has been reported in patients simultaneously receiving intravenous amphotericin B and leukocyte transfusions.

Concomitant use with methylprednisolone may cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure.

Concomitant use with corticosteroids may cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure.

Concomitant use with potassium-depleting agents increases hypokalemia risk. Cases of cardiac enlargement and congestive heart failure reported with concurrent amphotericin B and hydrocortisone.

Concomitant use may cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure.

Concomitant use with corticosteroids may cause hypokalemia, cardiac enlargement, and congestive heart failure. Close monitoring required.

Concomitant use with potassium-depleting agents can cause hypokalemia. Cases reported of cardiac enlargement and congestive heart failure with concurrent amphotericin B and hydrocortisone.

Nephrotoxic agent that may enhance potential for drug-induced renal toxicity. Use concomitantly only with great caution and intensive monitoring of renal function.

Concomitant or sequential use may have additive nephrotoxic effects; should be closely monitored and avoided if possible.

Concomitant use may result in cardiac enlargement and congestive heart failure, particularly due to potassium depletion.

Concomitant use may cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure. Close monitoring required.

May potentiate amphotericin B-induced hypokalemia, predisposing to cardiac dysfunction. Avoid concomitant use unless necessary; monitor serum electrolytes and cardiac function.

Concomitant use may cause hypokalemia and has been associated with cardiac enlargement and congestive heart failure.

Concomitant use with corticosteroids may cause hypokalemia and cases of cardiac enlargement and congestive heart failure have been reported.

Risk of nephrotoxicity may be increased when coadministered with valganciclovir. Monitor renal function closely.

Potential increase in serum creatinine and nephrotoxicity risk when coadministered with valganciclovir. Monitor renal function.

Potentially nephrotoxic and neurotoxic drug requiring renal function monitoring when used concurrently with vancomycin.

Imidazoles may induce fungal resistance to amphotericin B. Combination therapy should be administered with caution, especially in immunocompromised patients.

Amphotericin B potentiates cyclophosphamide's nephrotoxicity when used concomitantly or sequentially.

Highly protein-bound drug with narrow therapeutic index; dronabinol may displace amphotericin B from plasma proteins increasing free fraction. Monitor for adverse reactions.

Imidazoles may induce fungal resistance to amphotericin B. Combination therapy should be administered with caution, especially in immunocompromised patients.

Imidazoles may induce fungal resistance to amphotericin B. Combination therapy should be administered with caution, especially in immunocompromised patients.

Amphotericin B induces renal losses of magnesium.

Amphotericin B induces renal losses of magnesium, potentially leading to hypomagnesemia.

Imidazoles may induce fungal resistance to amphotericin B. Combination therapy should be administered with caution, especially in immunocompromised patients.

Concurrent use with hydrochlorothiazide may intensify electrolyte imbalance, particularly hypokalemia, though triamterene presence minimizes this effect.

Amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants. Serum potassium levels should be closely monitored.

Co-administration with micafungin did not alter micafungin pharmacokinetics.

Synergism or antagonism between clotrimazole and amphotericin B has not been reported.